Discounted Cash Flow (DCF) Analysis Levered
Knight Therapeutics Inc. (GUD.TO)
$4.41
+0.04 (+0.92%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12.50 | 47.46 | 199.52 | 243.48 | 293.56 | 765.23 | 1,994.71 | 5,199.60 | 13,553.75 | 35,330.42 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -5.74 | 4.60 | -12.21 | 44.62 | 40.48 | -15.66 | -40.81 | -106.39 | -277.33 | -722.91 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -3.87 | -2.95 | -20.67 | -224.18 | -25.82 | -227.14 | -592.09 | -1,543.40 | -4,023.17 | -10,487.17 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -9.61 | 1.65 | -32.87 | -179.57 | 14.66 | -242.80 | -632.91 | -1,649.79 | -4,300.50 | -11,210.08 |
Weighted Average Cost Of Capital
| Share price | $ 4.41 |
|---|---|
| Beta | 0.480 |
| Diluted Shares Outstanding | 114.89 |
| Cost of Debt | |
| Tax Rate | 32.00 |
| After-tax Cost of Debt | 5.77% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 6.893 |
| Total Debt | 77.70 |
| Total Equity | 506.67 |
| Total Capital | 584.37 |
| Debt Weighting | 13.30 |
| Equity Weighting | 86.70 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 12.50 | 47.46 | 199.52 | 243.48 | 293.56 | 765.23 | 1,994.71 | 5,199.60 | 13,553.75 | 35,330.42 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.74 | 4.60 | -12.21 | 44.62 | 40.48 | -15.66 | -40.81 | -106.39 | -277.33 | -722.91 |
| Capital Expenditure | -3.87 | -2.95 | -20.67 | -224.18 | -25.82 | -227.14 | -592.09 | -1,543.40 | -4,023.17 | -10,487.17 |
| Free Cash Flow | -9.61 | 1.65 | -32.87 | -179.57 | 14.66 | -242.80 | -632.91 | -1,649.79 | -4,300.50 | -11,210.08 |
| WACC | ||||||||||
| PV LFCF | -227.47 | -555.50 | -1,356.59 | -3,312.92 | -8,090.45 | |||||
| SUM PV LFCF | -13,542.93 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 6.74 |
| Free cash flow (t + 1) | -11,434.28 |
| Terminal Value | -241,229.57 |
| Present Value of Terminal Value | -174,098.31 |
Intrinsic Value
| Enterprise Value | -187,641.24 |
|---|---|
| Net Debt | 6.02 |
| Equity Value | -187,647.26 |
| Shares Outstanding | 114.89 |
| Equity Value Per Share | -1,633.27 |